First patient treated in TIKOMED’s Phase II study of clinical islet transplantation in patients with brittle diabetes

Viken – 12th February 2021 – TIKOMED, a specialty pharmaceutical company developing an infusion product for improving the outcome in cell therapies, today announced that the first patient has been treated in TIKOMED’s ongoing Phase II international, multicenter study – NNCIT-02.

In the NNCIT-02 study, brittle diabetes patients being transplanted with islets of Langerhans are treated with IBSOLVMIR® which has shown to be able to address the instant blood-mediated inflammatory reaction (IBMIR) occurring as an innate immune reaction to the infusion of transplanted cells. Previously, in both a patient study and pre-clinical work, IBSOLVMIR® has shown to be efficacious by decreasing the acute graft loss and helping the transplant to engraft.

“Despite an ongoing pandemic, we have successfully initiated the NNCIT-02 Islet Cell transplantation study for type 1 diabetic patients and we are excited to see how IBSOLVMIR® can support the transplantation by mitigating the IBMIR effect and facilitate engraftment. A product that could support a positive outcome in cell transplantation would be of great value for our patients”, said Torbjörn Lundgren, Principal investigator of the study, Karolinska University Hospital.

TIKOMED is now preparing to expand the use of IBSOLVMIR® through partnerships in the quickly expanding field of advanced therapies.

“We are very pleased that the first patient has been treated in this study and we are optimistic about IBSOLVMIR’s potential and future role in supporting graft optimization. This is the first study of a wider scope where we aim to demonstrate the benefits of IBSOLVMIR® treatment in combination with other therapeutic cells. IBSOLVMIR®, may prove to be the difference between successful and failed cell therapies.” said Adam Bruce – Executive Board Member and founder of TIKOMED.

Share on facebook
Share on twitter
Share on linkedin
Share on email